Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ACTRIMS 2023 | Remyelinating treatments under investigation in MS

Gustavo Della Flora Nunes, PhD, University of Colorado, Denver CO, discusses remyelinating therapies currently under investigation for the treatment of multiple sclerosis (MS). The rationale for promoting repair of myelin sheaths is compelling, however, to date, success in the clinic has been minimal. There remains a lack of knowledge regarding the mechanisms involved and how this translates to an efficacious remyelination strategy. One agent being studied is LL-341070, a thyromimetic prodrug shown to enhance oligodendrocyte regeneration in experimental models. The agent has been designed to optimize central versus peripheral exposure in several ways: the prodrug is only activated upon contact with FAAH which is expressed the brain; novel peripherally restricted FAAH inhibitors limit conversion in the gut and the liver; and the agent selectively targets thyroid hormone receptor beta (TRβ) over TRα. Dr Della Flora Nunes comments on the major questions that must be addressed to drive progress in this space. This interview took place at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2023 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.